查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1584624

CAR-T细胞疗法的全球市场：按药物适应症、按适应症、按最终用户、按地区、趋势分析、竞争格局、预测，2019-2030年

CAR-T Cell Therapy Market, By Drug Indication; By Indication; By End User; By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2030
出版日期: | 出版商: Blueweave Consulting | 英文 418 Pages | 商品交期: 2-3个工作天内

价格
简介目录

到 2030 年，全球 CAR-T 细胞疗法市场将扩大 6.2 倍，达到 570 亿美元

由于癌症发病率不断上升、对标靶治疗的需求激增以及技术进步的迅速采用，全球 CAR-T 细胞治疗市场正在蓬勃发展。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，2023 年全球 CAR-T 细胞疗法市场规模以金额为准91.1 亿美元。 BlueWeave预测，在2024年至2030年的预测期内，全球CAR-T细胞治疗市场规模将以30.20%的复合年增长率稳定成长，到2030年将达到568亿美元。全球 CAR-T 细胞治疗市场由几个关键因素推动，例如癌症盛行率的增加需要创新治疗以及对 CAR-T 疗法的需求不断增加。 CAR-T技术的进步将提高治疗的有效性和安全性。对针对性和个人化治疗的需求不断增长，进一步推动了市场的成长。此外，临床试验活动和法律规范的活性化正在促进研究和开发，促进市场扩张。

机会 - 扩展到其他适应症

随着新法规的扩展，全球 CAR-T 细胞治疗市场正在成长。 CAR-T疗法最初是针对白血病，现在正在研究针对固体癌和其他疾病。广泛的准入使患者能够获得并推动市场。正在进行的研究和临床试验旨在提高 CAR-T 疗法对这些疾病的疗效，并推动市场扩张。

地缘政治紧张局势加剧对全球 CAR-T 细胞治疗市场的影响

地缘政治紧张局势的加剧可能会扰乱供应链并增加投入成本，进而影响全球 CAR-T 细胞治疗市场。贸易限制以及政治和经济不稳定可能会减缓生产和分配。这些挑战可能迫使製造商寻找新的供应商并改变流程，从而提高消费者的价格并影响市场成长。

Yescarta 在全球 CAR-T 细胞治疗市场占有主要份额

由于其对某些血癌，特别是瀰漫性大 B 细胞淋巴瘤 (DLBCL) 的高效功效，Axicabtagene Ciloleucel (Yescarta) 细分市场在全球 CAR-T 细胞疗法市场中占据最大份额。 Yescarta在临床试验中的成功以及在各个地区的广泛采用为其在市场上的领先地位做出了贡献。全球CAR-T细胞疗法市场的其他主要适应症包括Brexucabtagene Autoleucel（Tecartus）、Ciltacabtagene Autoleucel（Carvykti）、Idecabtagene Vicleucel（Abecma）、Lisocabtagene Maraleucel（Breyanzi）和Tisagenlecleucel（Kymah）。

竞争格局

全球CAR-T细胞治疗市场竞争激烈，许多企业争夺更大的市场占有率。这些公司正在利用各种策略在全球 CAR-T 细胞治疗市场中占有一席之地，包括增加对研发活动的投资、併购、合资、联盟、许可协议以及新产品和服务的发布，并进一步加强这项策略。

本报告的详细分析提供了有关全球 CAR-T 细胞治疗市场的成长潜力、未来趋势和统计数据的资讯。它还重点关注推动市场总规模预测的因素。该报告致力于提供全球CAR-T细胞治疗市场的最新技术趋势以及产业见解，以帮助决策者做出策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 研究框架

第 2 章执行摘要

第三章 全球CAR-T细胞治疗市场洞察

  • 最终用户价值链分析
  • DROC分析
    • 生长促进因子
      • 癌症发生率上升
      • 细胞工程和基因重组技术的不断进步
      • 有利的监管地位：CAR-T细胞疗法
      • 製药公司、生技公司和投资者的兴趣增加
    • 抑制因素
      • CAR-T细胞治疗高成本
      • CAR-T 细胞疗法的可用性和可及性通常仅限于有限数量的患者。
      • CAR-T 细胞疗法相关的潜在副作用
    • 机会
      • 扩展到新的适应症
      • CAR-T细胞疗法与其他治疗方法结合
      • 基因组学和个人化医疗的进展
    • 任务
      • 与製造 CAR-T 细胞疗法相关的製造挑战
      • 确保 CAR-T 细胞治疗的适当报销
  • 科技进步/最新趋势
  • 法律规范
  • 波特五力分析

第四章全球CAR-T细胞治疗市场：行销策略

第五章全球CAR-T细胞治疗市场：价格分析

第六章全球CAR-T细胞治疗市场：区域分析

  • 全球 CAR-T 细胞治疗市场，区域分析，2023 年
  • 2024-2030年全球CAR-T细胞治疗市场吸引力分析

第七章 全球CAR-T细胞治疗市场概况

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按药物适应症
      • Axicabtagene Ciloleucel (Yescarta)
      • Brexucabtagene Autoleucel (Tecartus)
      • Ciltacabtagene Autoleucel (Carvykti)
      • Idecabtagene Vicleucel (Abecma)
      • Lisocabtagene Maraleucel (Breyanzi)
      • Tisagenlecleucel (Kymriah)
      • 其他的
    • 按指示
      • 急性淋巴性白血病
      • 非何杰金氏淋巴瘤
      • 多发性骨髓瘤
    • 按最终用户
      • 医院
      • 肿瘤治疗中心
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第八章 北美CAR-T细胞治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按药物适应症
    • 按指示
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第九章欧洲CAR-T细胞治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按药物适应症
    • 按指示
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第十章亚太CAR-T细胞治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按药物适应症
    • 按指示
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他地区

第十一章拉丁美洲CAR-T细胞治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按药物适应症
    • 按指示
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第十二章中东和非洲CAR-T细胞治疗市场

  • 2019-2030年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按药物适应症
    • 按指示
    • 按最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东/非洲

第十三章竞争格局

  • 主要参与者及其产品列表
  • 2023年全球CAR-T细胞治疗企业市场占有率分析
  • 透过管理参数进行竞争基准基准化分析
  • 重大策略发展（合併、收购、联盟等）

第14章 地缘政治紧张局势升级对全球CAR-T细胞治疗市场的影响

第十五章 公司简介（公司简介、财务矩阵、竞争格局、关键人员、主要竞争对手、联络方式、策略展望、SWOT分析）

  • Bristol-Myers Squibb
  • Sorrento Therapeutics, Inc.
  • Celgene Corporation
  • Merck &Co., Inc.
  • Novartis AG
  • Celyad Oncology
  • Juno Therapeutics, Inc.
  • Autolus Therapeutics
  • Cellectis
  • Miltenyi Biotech
  • Intellia Therapeutics
  • Pfizer, Inc.
  • 其他主要企业

第十六章 主要策略建议

第十七章调查方法

简介目录
Product Code: BWC24781

Global CAR-T Cell Therapy Market Zooms 6.2X to Touch Whopping USD 57 Billion by 2030

Global CAR-T Cell Therapy Market is thriving due to increasing prevalence of cancer, a spurring demand for targeted therapies, and rapid adoption of technological advancements.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global CAR-T Cell Therapy Market size by value at USD 9.11 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global CAR-T Cell Therapy Market size to expand at a robust CAGR of 30.20% reaching a value of USD 56.80 billion in 2030. Global CAR-T Cell Therapy Market is driven by several key factors, including the increasing prevalence of cancer necessitates innovative treatments, boosting demand for CAR-T therapies. Advancements in CAR-T technology enhance treatment efficacy and safety. Growing demand for targeted and personalized therapies further propels market growth. Additionally, rising clinical trial activities and supportive regulatory frameworks encourage research and development, fostering market expansion.

Opportunity - Expansion into other Indications

Global CAR-T Cell Therapy Market is growing with the expansion of new regulations. Initially focused on leukemia, CAR-T therapies are now being investigated for solid tumors and other diseases. Wide access enables patients to access and drives the market. Ongoing research and clinical trials are aimed at increasing the efficacy of CAR-T therapies for the conditions, driving market expansion.

Impact of Escalating Geopolitical Tensions on Global CAR-T Cell Therapy Market

Increasing geopolitical tensions could impact Global CAR-T Cell Therapy Market by disrupting supply chains and increasing input costs. Trade restrictions and political and economic instabilities could delay production and distribution. These challenges are forcing manufacturers to seek new sources and change processes, potentially increasing prices for consumers and affecting market growth.

Yescarta Holds Major Share of Global CAR-T Cell Therapy Market

The Axicabtagene Ciloleucel (Yescarta) segment accounts for the largest market share of Global CAR-T Cell Therapy Market by drug indication, due to its high efficacy in treating certain types of blood cancers, particularly diffuse large B-cell lymphoma (DLBCL). Yescarta's success in clinical trials and its widespread adoption in various regions contribute to its leading position in the market. The other major drug indication segments in Global CAR-T Cell Therapy Market include Brexucabtagene Autoleucel (Tecartus), Ciltacabtagene Autoleucel (Carvykti), Idecabtagene Vicleucel (Abecma), Lisocabtagene Maraleucel (Breyanzi), and Tisagenlecleucel (Kymriah).

Competitive Landscape

Global CAR-T Cell Therapy Market is fiercely competitive, with numerous companies vying for a larger market share. Major companies in the market include Bristol-Myers Squibb, Sorrento Therapeutics, Inc., Celgene Corporation, Merck & Co., Inc., Novartis AG, Celyad Oncology, Juno Therapeutics, Inc., Autolus Therapeutics, Cellectis, Miltenyi Biotech, Intellia Therapeutics, and Pfizer, Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global CAR-T Cell Therapy Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global CAR-T Cell Therapy Market. It also highlights the factors driving forecasts of total Market size. The report promises to provide recent technological trends in Global CAR-T Cell Therapy Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the Market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global CAR-T Cell Therapy Market Insights

  • 3.1. End User Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Continuous advancements in cell engineering and genetic modification techniques
      • 3.2.1.3. Favorable regulatory landscape: for CAR-T cell therapy
      • 3.2.1.4. Growing interest from pharmaceutical companies, biotech firms, and investors
    • 3.2.2. Restraints
      • 3.2.2.1. High costs of CAR-T cell therapy
      • 3.2.2.2. Limited availability and access to CAR-T cell therapy is often restricted to a limited number of patients.
      • 3.2.2.3. Potential side effects associated with CAR-T cell therapy
    • 3.2.3. Opportunities
      • 3.2.3.1. Expansion into new indications
      • 3.2.3.2. Combining CAR-T cell therapy with other treatments
      • 3.2.3.3. Advancements in genomics and personalized medicine
    • 3.2.4. Challenges
      • 3.2.4.1. Manufacturing challenges associated with the production of CAR-T cell therapies
      • 3.2.4.2. Ensuring adequate reimbursement for CAR-T cell therapy
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global CAR-T Cell Therapy Market: Marketing Strategies

5. Global CAR-T Cell Therapy Market: Pricing Analysis

6. Global CAR-T Cell Therapy Market: Geography Analysis

  • 6.1. Global CAR-T Cell Therapy Market, Geographical Analysis, 2023
  • 6.2. Global CAR-T Cell Therapy, Market Attractiveness Analysis, 2024-2030

7. Global CAR-T Cell Therapy Market Overview

  • 7.1. Market Size & Forecast, 2019-2030
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Indication
      • 7.2.1.1. Axicabtagene Ciloleucel (Yescarta)
      • 7.2.1.2. Brexucabtagene Autoleucel (Tecartus)
      • 7.2.1.3. Ciltacabtagene Autoleucel (Carvykti)
      • 7.2.1.4. Idecabtagene Vicleucel (Abecma)
      • 7.2.1.5. Lisocabtagene Maraleucel (Breyanzi)
      • 7.2.1.6. Tisagenlecleucel (Kymriah)
      • 7.2.1.7. Others
    • 7.2.2. By Indication
      • 7.2.2.1. Acute Lymphoblastic Leukemia
      • 7.2.2.2. Non-Hodgkin Lymphoma
      • 7.2.2.3. Multiple Myeloma
    • 7.2.3. By End User
      • 7.2.3.1. Hospitals
      • 7.2.3.2. Oncology Treatment Centers
    • 7.2.4. By Region
      • 7.2.4.1. North America
      • 7.2.4.2. Europe
      • 7.2.4.3. Asia Pacific (APAC)
      • 7.2.4.4. Latin America (LATAM)
      • 7.2.4.5. Middle East and Africa (MEA)

8. North America CAR-T Cell Therapy Market

  • 8.1. Market Size & Forecast, 2019-2030
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Indication
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.1.1. By Drug Indication
      • 8.2.4.1.2. By Indication
      • 8.2.4.1.3. By End User
      • 8.2.4.2. Canada
      • 8.2.4.2.1. By Drug Indication
      • 8.2.4.2.2. By Indication
      • 8.2.4.2.3. By End User

9. Europe CAR-T Cell Therapy Market

  • 9.1. Market Size & Forecast, 2019-2030
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Indication
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Germany
      • 9.2.4.1.1. By Drug Indication
      • 9.2.4.1.2. By Indication
      • 9.2.4.1.3. By End User
      • 9.2.4.2. United Kingdom
      • 9.2.4.2.1. By Drug Indication
      • 9.2.4.2.2. By Indication
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Italy
      • 9.2.4.3.1. By Drug Indication
      • 9.2.4.3.2. By Indication
      • 9.2.4.3.3. By End User
      • 9.2.4.4. France
      • 9.2.4.4.1. By Drug Indication
      • 9.2.4.4.2. By Indication
      • 9.2.4.4.3. By End User
      • 9.2.4.5. Spain
      • 9.2.4.5.1. By Drug Indication
      • 9.2.4.5.2. By Indication
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Belgium
      • 9.2.4.6.1. By Drug Indication
      • 9.2.4.6.2. By Indication
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Russia
      • 9.2.4.7.1. By Drug Indication
      • 9.2.4.7.2. By Indication
      • 9.2.4.7.3. By End User
      • 9.2.4.8. The Netherlands
      • 9.2.4.8.1. By Drug Indication
      • 9.2.4.8.2. By Indication
      • 9.2.4.8.3. By End User
      • 9.2.4.9. Rest of Europe
      • 9.2.4.9.1. By Drug Indication
      • 9.2.4.9.2. By Indication
      • 9.2.4.9.3. By End User

10. Asia Pacific CAR-T Cell Therapy Market

  • 10.1. Market Size & Forecast, 2019-2030
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Indication
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
      • 10.2.4.1. China
      • 10.2.4.1.1. By Drug Indication
      • 10.2.4.1.2. By Indication
      • 10.2.4.1.3. By End User
      • 10.2.4.2. India
      • 10.2.4.2.1. By Drug Indication
      • 10.2.4.2.2. By Indication
      • 10.2.4.2.3. By End User
      • 10.2.4.3. Japan
      • 10.2.4.3.1. By Drug Indication
      • 10.2.4.3.2. By Indication
      • 10.2.4.3.3. By End User
      • 10.2.4.4. South Korea
      • 10.2.4.4.1. By Drug Indication
      • 10.2.4.4.2. By Indication
      • 10.2.4.4.3. By End User
      • 10.2.4.5. Australia & New Zealand
      • 10.2.4.5.1. By Drug Indication
      • 10.2.4.5.2. By Indication
      • 10.2.4.5.3. By End User
      • 10.2.4.6. Indonesia
      • 10.2.4.6.1. By Drug Indication
      • 10.2.4.6.2. By Indication
      • 10.2.4.6.3. By End User
      • 10.2.4.7. Malaysia
      • 10.2.4.7.1. By Drug Indication
      • 10.2.4.7.2. By Indication
      • 10.2.4.7.3. By End User
      • 10.2.4.8. Singapore
      • 10.2.4.8.1. By Drug Indication
      • 10.2.4.8.2. By Indication
      • 10.2.4.8.3. By End User
      • 10.2.4.9. Vietnam
      • 10.2.4.9.1. By Drug Indication
      • 10.2.4.9.2. By Indication
      • 10.2.4.9.3. By End User
      • 10.2.4.10. Rest of APAC
      • 10.2.4.10.1. By Drug Indication
      • 10.2.4.10.2. By Indication
      • 10.2.4.10.3. By End User

11. Latin America CAR-T Cell Therapy Market

  • 11.1. Market Size & Forecast, 2019-2030
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Indication
    • 11.2.2. By Indication
    • 11.2.3. By End User
    • 11.2.4. By Country
      • 11.2.4.1. Brazil
      • 11.2.4.1.1. By Drug Indication
      • 11.2.4.1.2. By Indication
      • 11.2.4.1.3. By End User
      • 11.2.4.2. Mexico
      • 11.2.4.2.1. By Drug Indication
      • 11.2.4.2.2. By Indication
      • 11.2.4.2.3. By End User
      • 11.2.4.3. Argentina
      • 11.2.4.3.1. By Drug Indication
      • 11.2.4.3.2. By Indication
      • 11.2.4.3.3. By End User
      • 11.2.4.4. Peru
      • 11.2.4.4.1. By Drug Indication
      • 11.2.4.4.2. By Indication
      • 11.2.4.4.3. By End User
      • 11.2.4.5. Rest of LATAM
      • 11.2.4.5.1. By Drug Indication
      • 11.2.4.5.2. By Indication
      • 11.2.4.5.3. By End User

12. Middle East and Africa CAR-T Cell Therapy Market

  • 12.1. Market Size & Forecast, 2019-2030
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Drug Indication
    • 12.2.2. By Indication
    • 12.2.3. By End User
    • 12.2.4. By Country
      • 12.2.4.1. Saudi Arabia
      • 12.2.4.1.1. By Drug Indication
      • 12.2.4.1.2. By Indication
      • 12.2.4.1.3. By End User
      • 12.2.4.2. UAE
      • 12.2.4.2.1. By Drug Indication
      • 12.2.4.2.2. By Indication
      • 12.2.4.2.3. By End User
      • 12.2.4.3. Qatar
      • 12.2.4.3.1. By Drug Indication
      • 12.2.4.3.2. By Indication
      • 12.2.4.3.3. By End User
      • 12.2.4.4. Kuwait
      • 12.2.4.4.1. By Drug Indication
      • 12.2.4.4.2. By Indication
      • 12.2.4.4.3. By End User
      • 12.2.4.5. South Africa
      • 12.2.4.5.1. By Drug Indication
      • 12.2.4.5.2. By Indication
      • 12.2.4.5.3. By End User
      • 12.2.4.6. Nigeria
      • 12.2.4.6.1. By Drug Indication
      • 12.2.4.6.2. By Indication
      • 12.2.4.6.3. By End User
      • 12.2.4.7. Algeria
      • 12.2.4.7.1. By Drug Indication
      • 12.2.4.7.2. By Indication
      • 12.2.4.7.3. By End User
      • 12.2.4.8. Rest of MEA
      • 12.2.4.8.1. By Drug Indication
      • 12.2.4.8.2. By Indication
      • 12.2.4.8.3. By End User

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global CAR-T Cell Therapy Company Market Share Analysis, 2023
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

14. Impact of Escalating Geopolitical Tensions on Global CAR-T Cell Therapy Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)

  • 15.1. Bristol-Myers Squibb
  • 15.2. Sorrento Therapeutics, Inc.
  • 15.3. Celgene Corporation
  • 15.4. Merck & Co., Inc.
  • 15.5. Novartis AG
  • 15.6. Celyad Oncology
  • 15.7. Juno Therapeutics, Inc.
  • 15.8. Autolus Therapeutics
  • 15.9. Cellectis
  • 15.10. Miltenyi Biotech
  • 15.11. Intellia Therapeutics
  • 15.12. Pfizer, Inc.
  • 15.13. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable